Etravirine drug interactions;Interacciones medicamentosas de etravirina

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue SUPPL. 2, 2009, Pages 27-31

  Pérez, Vicente Estrada ^a   Sánchez Parra, Clara ^a   Villar, Sergio Serrano ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Drug interactions; Etravirine

Indexed keywords

ATAZANAVIR; ATORVASTATIN; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; LOPINAVIR; METHADONE; NEVIRAPINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; RALTEGRAVIR; RANITIDINE; RIFABUTIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANALGESICS; ANESTHETICS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTICONVULSANTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CONTRACEPTIVES, ORAL, HORMONAL; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROSOMES, LIVER; PIPERAZINES; PURINES; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SULFONES;

EID: 75149152597     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(09)73216-1     Document Type: Article

References (29)

1. D.S. Schiller, and M. Youssef-Bessler Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV Clin Ther 31 2009 692 704
2. Informe público europeo de evaluación (EPAR), Intelence European Medicines Agency (EMEA). Documento EMEA/H/C/900 [consultado 14-7-2009]. Disponible en: http://www.emea.europa.eu
3. M. Schöller-Gyre, A. Raaof, G. Mannens, S. Bollen, T.N. Kakuda, D. Woodfall, et al. Mass-balance of 14C-labelled TMC125 in healthy volunteers 8th International Workshop on Clinical Pharmacology of HIV Therapy Budapest 2007 Apr 16-18. Abstract 78
4. P. Baede, S. Piscitelli, N. Graham, and G. Van't Klooster Drug interactions with TMC125, a Potent Next Generation NNRTI Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego. September 27-30 2002 Abstract A-1827
5. M. Schöller-Gyre, R. Hoetelmans, S. Bollen, K. Vandermeulen, M. Peeters, L. Bastiaanse, et al. No significant interaction between TMC125 and didanosine in healthy volunteers 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro 2005 Abstract WePe3.3C16
6. M. Schöller-Güyre, C. Debroye, B. Woodfall, J. Witek, G. De Smedt, and R.M. Hoetelmans Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco (CA) 2006 Sep 27-30. Abstract A-371
7. T. Kakuda, M. Schöller-Gyüre, B. Woodfall, G. De Smedt, M. Peeters, K. Vandermeulen, et al. TMC125 in combination with other medications: summary of drug-drug interaction studies 8th International Congress on Drug Therapy in HIV Infection Glasgow. 12-16 November 2006 Oral presentation PL5.2
8. M. Harris, C. Zala, S. Ramírez, B. Woodfall, M. Peeters, M. Scholler, et al. Pharmacokinetics and safety of adding TMC125 to stable regimens of saquinavir, lopinavir and ritonavir in HIV+adults 13th Conference on Retroviruses and Opportunistic Infections Denver (CO). 5-8 Feb 2006 Abstract 575
9. M. Schöller Gyüre, B. Woodffall, T. De Marez, G. De Smedt, M. Peeters, K. Vandermeulen, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir 8th Internacional Congress on Drug Therapy in HIV Infection Glasgow. Nov 12-16 2006 Abstract P278
10. M. Schöller, M. Kraft, R. Hoetelmans, V. Vyncke, K. Vandermeulen, M. Peeters, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir in healthy subjects 13th Conference on Retroviruses and Opportunistic Infections Denver (CO). 5-8 Feb 2006 Abstract 583
11. M. Schöller-Gyüre, B. Woodfall, S. Bollen, M. Peeters, K. Vandermeulen, and R. Hoetelmans Pharmacokinetics of amprenavir and TMC125 in HIV infected volunteers receiving TMC125 with fosamprenavir/ritonavir 46th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco (CA) 2006 Sep 27-30. Abstract A-370
12. S.C. Piscitelli, P. Baede, G. Van't Klooster, and N. Graham TMC125 does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego (CA) 2002 sep 27-30. Abstract A-1824
13. M. Schöller-Gyüre, T.N. Kakuda, S.H. Akuma, I. De Clero, G. De Smedt, K. Spittaels, et al. Pharmacokinetic interaction between etravirine and lopinavir/ritonavir 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) San Francisco, California, USA. September 2009 A1-1298
14. A. Lazzarin, T. Campbell, B. Clotet, M. Johnson, C. Katlama, and A. Moll Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 39 48 (Pubitemid 47017467)
15. J.V. Madruga, P. Cahn, B. Grinsztejn, R. Haubrich, J. Lalezari, and A. Mills Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial Lancet 370 2007 29 38 (Pubitemid 47017466)
16. M. Schöller-Gyüre, T.N. Kakuda, V. Sekar, B. Woodfall, G. De Smedt, and E. Lefebvre Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers Antivir Ther 12 2007 789 796 (Pubitemid 47235493)
17. J. Lalezari, E. DeJesus, O. Osiyemi, P. Ruane, Z. Haigney, R. Ryan, et al. Pharmacokinetics of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults 9th International Congress on Drug Therapy in HIV Infection Glasgow. November 9-13 2008 Abstract P245
18. J. Davis, M. Schöller-Gyre, T.N. Kakuda, C. Ridgway, S. Tweedy, N. Ndongo, et al. An open, randomized, two period, crossover study in 2 cohorts to investigate the effect of steady state TMC125 and the combination of TMC/darunavir/ritonavir on the steady state pharmacokinetics of oral maraviroc in healthy subjects 11th European AIDS Conference Madrid, Spain. Oct 24-27 2007 Abstract P4.3/02
19. A. Menard, C. Solas, S. Mokthari, S. Bregigeon, M.P. Drogoul, C. Tamalet, et al. Etravirine-raltegravir, a marked interaction in HIV-1 infected patients: about four cases AIDS 23 2009 869 871
20. M.S. Anderson, T.N. Kakuda, W. Hanley, J. Miller, J.T. Kost, R. Stoltz, et al. Minimal pharmacokinetic interaction between the human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects Antimicrob Agents Chemother 52 2008 4228 4232
21. L. Wittkop, D. Breilh, D. Da Silva, P. Duffau, P. Mercié, I. Raymond, et al. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort J Antimicrob Chemother 63 2009 1251 1255
22. S. Ramanathan, T.N. Kakuda, R. Mack, S. West, and B.P. Kearney Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine Antivir Ther 13 2008 1011 1017
23. M. Schöller-Gyüre, B. Woodfall, C. Debroye, T. De Marez, M. Peeters, K. Vandermeulen, et al. Pharmacokinetic interaction between TMC125 and rifabutin 44th Annual Meeting of the Infectious Diseases Society of America Toronto. 12-15 Oct 2006 Abstract 963
24. Etravirine interactions chart [consultado 14-7-2009]. Disponible en: http://www.hiv-druginteractions.org
25. M. Schöller-Gyüre, W. Van den Brink, T.N. Kakuda, B. Woodfall, G. De Smedt, and H. Vanaken Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers J Clin Pharmacol 48 2008 322 329 (Pubitemid 351257768)
26. M. Schöller-Gyüre, T.N. Kakuda, G. De Smedt, B. Woodfall, S. Bollen, M. Peeters, et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitor TMC125 and atorvastatin in HIV-negative volunteers 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention Sydney. 22-25 Jul 2007 Abstract WEPEA 106
27. I.D. Deeks, and G.M. Keating Etravirine Drugs 68 2008 2357 2372
28. M. Schöller-Gyüre, T.N. Kakuda, G. De Smedt, H. Vanaken, M.P. Bouche, M. Peeters, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers Br J Pharmacol 66 2008 508 516
29. T. Kakuda, M. Schöller-Gyüre, B. Woodfall, G. De Smedt, M. Peeters, K. Vandermeulen, et al. TMC125 in combination with other medications: summary of drug-drug interaction studies 8th International Congress on Drug Therapy in HIV Infection Glasgow. 12-16 November 2006 Oral presentation PL5.2